NCT07186062CompletedPhase 4
Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
This study aimed to assess and compare the cardiac, renal, and clinical efficacy of Levosimendan (LEV), Dobutamine (DOB), and milrinone (MIL) in cases with acute decompensated heart failure (ADHF) complicated by renal impairment, with a focus on their role in the management of cardiorenal syndrome (CRS).
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 10 Sept 2025
- Start date
- 1 Jun 2022
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Heart failure
- NCT number
- NCT07186062
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 60
- From 1 Jun 2022 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent MI or acute coronary syndrome within the previous two months
- Known history of kidney disease diagnosed prior to HF
- Administration of contrast agents or nephrotoxic drugs within the previous seven days
Other illness
- Resting heart rate exceeding 120 beats per minute
- Structural cardiac conditions
- Active acute inflammatory or infectious diseases.
Age
- Age younger than 18 years
Other
- Cases were excluded from the study if they met any of the following criteria:
- Untreated acute HF
- Diagnosed pulmonary embolism
- Severe liver dysfunction (Child C)
Who the study is looking for
- Adult (\>18 years old) patients with ADHF (LVEF ≤ 40% documented prior to enrollment) admitted to the ICU with renal impairment (estimated GFR between 30 and 60 mL/min/1.73 m², calculated using the Modification of Diet in Renal Disease Study equation (MDRD equation)) and require inotropic support.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine-Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.